Search published articles


Showing 8 results for Moghimi

M Moghimi, M Karimi, K Alimoghadam,
Volume 15, Issue 60 (5-2007)
Abstract

Sjögren’s syndrome (SS) is a systemic autoimmune disease that presents with sicca symptoms of the main mucosal surfaces. The spectrum of disease extends from sicca syndrome to systemic involvement and may be complicated by the development of lymphoma. Many types of malignant and pseudo malignant diseases have been reported, but the most important is non Hodgkin lymphoma. We here present a 45 year-old woman with SS that referred with pancytopenia. By molecular and histochemical techniques a diagnosis of acute myeloblastic leukemia of M3 type (AML-M3) was made for this patient.


B Moghimi- Dehkordi, Ar Rajaeefard, A Safaaee, Hr Tabatabaee, B Zeighami, Sz Tabeie,
Volume 16, Issue 63 (6-2008)
Abstract

Background and Objective: Esophageal cancer is the 6th common cancer in Iran. Affected patients have a relatively short lifetime, as this cancer is usually diagnosed in advanced stages. This study was conducted to estimate survival and factors related to it in patients with esophageal cancer. Materials and Methods: All patients definitely diagnosed as esophageal cancer, registered in Fars Cancer Registry Center, were investigated. Required information was gathered from cancer registry forms and other resources. 1- to 5-year survival rates were estimated using life-table method. Wilcoxon test was used to compare survival rates between subgroups. All data were analyzed by SPSS software. Results: Of 161cases, 61.5% were male. Mean age of patients was 64.6±13.10 years and 57.6±11.9 years in male and female, respectively. Overall survival rates at 1- to 5-years after diagnosis were: 58, 33, 18, 15 and 9 percent, respectively. Factors such as age at time of diagnosis, Presence of metastasis, histologic grade, type of first treatment, occupation in males, ethnicity and number of household showed to have a significant effect on prognosis. Conclusion: According to this study and similar studies carried out, screening and early detection of patients (in lower ages, and lower stages) is emphasized.


S Setodeh, Sn Hoseini, Sn Mousavinasab, Mh Moghimi, D Nazemi Salman, A Shaghaghi, M Nazarian,
Volume 17, Issue 67 (8-2009)
Abstract

Background and Objective: Due to fears of postoperative complications following upper gastrointestinal surgeries (UGI), fasting before bowl function recovery is a traditional practice, but fasting following elective surgery is controversial. The aim of this study was to compare early oral feeding versus traditional oral feeding in patients who underwent UGI surgeries. Materials and Methods: Fifty two patients who underwent UGI anastomosis or surgery for various reasons were randomly divided into early oral feeding (EOF) group and traditional oral feeding (TOF) group. The nasogastric tube (NGT) removal time, tolerance of oral feeding, ileuses, nausea and vomiting, vital sign before and after surgery, postoperative stay, patients’ satisfaction and complications were recorded. Results: The mean time of NGT removal was 1.62 ±0.49 and 4.61±1.99 days in EOF group and TOF group respectively (p=0.0005). The mean start time of oral feeding was 2.04 ± 0.19 and 5.87 ± 1.32 days in the EOF group and TOF group respectively (p=0.0005). Tolerance of oral feeding was seen in 24 (92.3%) patients and 21 (91.3%) patients in the EOF and TOF groups respectively. Duration of hospital stay following surgery was 5.62 days in the EOF group and 8.04 days in the TOF group. 24(92.3%) out of 26 patients in the EOF group were satisfied with oral feeding that started in the second postoperative day. 13 patients (56.5%) complained of delay feeding in the TOF group. Conclusion: The results of the present study suggest that early oral feeding following upper gastrointestinal anastomosis or surgery is safe and can result in a shorter hospital stay and less cost.


M Jamehshorani, R Eghdam Zamiri, M Moghimi,
Volume 20, Issue 78 (3-2012)
Abstract

Gastric cancer is one of the most common cancers in the world that can metastasize to other sites. The most common sites of metastasis are liver, lung, bone, and adrenal glands. Skin metastasis in gastric cancer is rare, and it usually occurs after diagnosis of primary cancer (1). The patient reported here is a 65-years old male with gastric adenocarcinoma that in the course of chemotherapy came down with some skin lesions. The biopsy report points to skin metastasis from gastric cancer. In spite of good systemic response to chemotherapy, the lesions progressed. Skin metastasis has poor prognosis, and it is a sign of disease diffusion (2).


R Eghdam Zamiri, M Moghimi, N Mosavi Nasab, H Amirmoghadami, M Joghatae , A Feizi,
Volume 20, Issue 81 (9-2012)
Abstract

Background and Objective: Elevation of the b-HCG serum levels has been reported in several tumors including breast cancer, and it is usually associated with aggressiveness. The aim of this study was to examine the possible correlation between the b-HCG serum levels and different grades of breast cancer tumors in patients undergoing chemotherapy. Materials and Methods: This cross-sectional study was conducted in the city of Zanjan during 2009-10. Serum samples from 56 cases of breast cancer patients were collected after surgery and prior to chemotherapy for analysis of total free b-HCG by electro chemiluminescence immunoassay, and the same procedure was repeated after 8 courses of chemotherapy. The b-HCG serum levels were compared in poor versus mild to moderate grades before and after chemotherapy. Results: In 37 cases of mild to moderate grade tumors, the mean b-HCG level was 1.09 ±1.4 miu/ml compared with 1.2 ±0.3 miu/ml (P= 0.75) in 29 cases of poor grade tumors. The mean b-HCG levels before and after chemotherapy were 1.15 ±1.4 miu/ml and 1.17 ±1.4 miu/ml (P=0.24), respectively. Conclusion: We did not find any significant association between the b-HCG serum levels and breast cancer tumor grades. Furthermore, chemotherapy does not appear to have an effect on b-HCG serum levels.


Mr Jamshidi, Mh Moghimi, S Madani, S Izadi, B 2falakolaflaki ,
Volume 23, Issue 98 (5-2015)
Abstract

Background and Objective: Post operative nausea and vomiting (PONV) are unpleasant feelings which frequently occur after laparoscopic cholecystectomy. The aim of this study was to compare the effectiveness of dexamethasone and propofol in prevention of PONV in patients undergoing laparoscopic cholecystectomy. Materials and Methods: 60 patients with ASA status 1-2, who had undergone laparoscopic cholecystectomy with similar general anesthesia were selected and were randomly assigned to one of the three groups (20 patients in each group). Group I received 0.5 mg/kg propofol (i.v), group II received 8 mg dexamethasone (i.v) and group III received normal salin 9.0% (i.v) as placebo, following the completion of surgery, 1 and 24 hours after the surgery patients with 0-2 level of consciousness were questioned about the presence of nausea and vomiting. Results: Over 1 to 24 hours after the surgery, PONV in the dexamethasone group was significantly less than the other groups. Also the incidence of PONV in the Propofol group was lower compared to Placebo group. Conclusion: A single dose of dexamethasone after surgery is effective in prevention of PONV in laparoscopic cholecystectomy. Also the incidence of PONV can be effectively reduced with Propofol. References 1- Fujii Y, Nakayama M. Prevention of postoperative nausea and vomiting with a small dose of propofol alone and combined with dexamethasone in patients undergoing laparoscopic cholecystectomy: A prospective, randomized, double-blined study. Surge Endosc. 2008 22: 1268-71. 2- Wang JJ, Ho ST, Liu YH, et al. Dexamethasone reduce nausea and vomiting after laparoscopic cholecystectomy. Br J Anaesth. 1999 83: 772-5. 3- Bisgaard T, Klarskov B, Kehlet H, Rosenberg J. Preoperative dexamethasone improve surgical outcome after laparoscopic cholecystectomy. Ann Surg. 2003 238: 651-60. 4- Fujii Y. Management of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Surg Endosc. 2011 25: 691-5. 5- Wang JJ, Ho ST, Uen YH, et al. Small dose dexamethasone reduce nausea and vomiting after laparoscopic cholecystectomy: A comparison of tropisetron with saline. Anesth Analg. 2002 95: 229-32. 6- Fukami Y, Terasaki M, Okamoto Y, et al. Efficacy of preoperative dexamethasone in patients with laparoscopic cholecystectomy: A prospective, randomized, double-blined study. J Hepatobiliary Pancreat Surg. 2009 16: 367-71. 7- Erhan Y, Erhan E, Aydede H, Yumus O, Yentur A. Ondansetron, granisetrone and dexamethasone compared for the prevention of postoperative nausea and vomiting in patients undergoing laparascopic cholecystectomy: A randomized placebo-controlled study. Surg Endosc. 2008 22: 1487-92. 8- Yoo YC, Bai SJ, Lee KY, Shin S, Choi EK, Lee JW. Total intravenous anesthesia with propofol reduces prostoprative nausea and vomiting in patients undergoing robot assisted laparascopic radical prostatectomy. Yonsei Med J. 2012 53: 1197-1202. 9- Arsalan M, Demir ME. Prevention of postoperative nausea and vomiting with a small dose of propofol combined with dexamethasone 4 mg or dexamethasone 8 mg in patients undergoing middle ear surgery: a prospective, randomized, double-blind study. Bratisl Lek Listy. 2011 112: 332-6. 10- Sanchez-Rodriquez PE, Fuentes Orozco C, Gonzalez Ojeda A. Effect of dexamethasone on postoperative symptom in patient undergoing elective laparoscopic cholecystectomy. World J Surgery. 2010 34: 895-900. 11- Fujli Y, Itakura M. Reduction of postoperative nausea, vomiting, and analgesic requirement with dexamethasone for patients undergoing laparoscopic cholecystectomy. Surg Endosc. 2010 24: 692-6. 12- Hosseini N, Mousavi nassab N, Salimi H. The assessment of result of laparoscopic cholecystectomy in Valiasr and Shafeiieh hospital in Zanjan. Zanjan Univ Med Sci J. 2005 50: 51-55. 13- Ryu JH, Chang JE, Kim tlR, Hwang JW, Oh AY, Do SH. Ramosetron vs ramosetron plus dexamethasone for the prevention of postoperative nausea and vomiting (PONV) after laparoscopic chole cystectomy prospectiue, romdomized, and double- blind study. Int J Surg. 2013 11: 183-7. 14- Fujii Y, Itakura M, Low dose propofol to prevent nausea and vomiting after laparoscopic surgery. Int J Gynecol. 2009 106: 50-20. 15- Nesek-Adam V, Grizelj-Stojcic E, Rasic Z, Cala Z, Mrsic V, Smiljanic A. Comparison of dexamethasone, Metoclopramid and their combination in the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Suvg Endosc. 2007 21: 607-12.


R Eghdam Zamiri , Sh Shokoufi, Z Ghadimi, Ss Baba Ali, S Jafari, B Talebi Pour, M Nazarian, S Palizi , M Moghimi,
Volume 23, Issue 101 (8-2015)
Abstract

Background and Objective: Upper gastro intestinal cancers are considered to be a global health problem and gastric cancer is the fourth common malignancy worldwide. In cancer patients, low levels of albumin,
C-reactive protein and platelets are considered as bad prognostic factors. The objective of this study was to evaluate the levels of Albumin (Alb), C-reactive protein (CRP), and Platelets in patients admitted to Endoscopy Unit of Vali-e-Asr Hospital in Zanjan in 2011-2012.

Materials and Methods: 308 patients who had been admitted for upper gasterointestinal endoscopy to Endoscopy Unit of Vali-e-Asr Hospital in Zanjan were entered into this study. Through the upper endoscopy of all abnormal lesions went through biopsy and pathological studies were followed.

Results: Patients were assigned to three groups of normal, benign and malignant lesions and their platelets, albumin levels, BMI and C-reactive protein were measured and compared as prognostic factors. The mean BMI, in the malignant group was significantly lower than the other two groups) PV=0.051(. The mean values of serum albumin in the malignant group was significantly lower than the other two groups (PV=0.023). Meanwhile, the average level of CRP and platelets in the malignant group was significantly higher than the other two groups.  

Conclusion: Due to the high prevalence of gastrointestinal malignancies in Iran, measurement of albumin, C-reactive protein and platelet levels can be an efficient approach to diagnose or prognosis in these diseases.


M Hosseini, A Mellati, Ss Mousavi, Mh Moghimi, A Ramezani,
Volume 25, Issue 109 (4-2017)
Abstract

Background and Objective: Several reports indicate the effect of obesity on the rise of breast cancer prevalence in different societies. Several laboratory methods have been applied in order to understand molecular mechanisms and biochemical markers associated with breast cancer, many of which are still unknown. In this study, we investigate the relation between protein profile of breast tumor tissue and body mass index (BMI) in women with invasive ductal breast cancer.

Materials and Methods: In this descriptive analytical study, 10 patients diagnosed with invasive ductal breast cancer were chosen and divided into two groups based on their BMI, higher mean (33.41) and lower mean (26.04). Homogenized tumor proteins were analyzed with proteomics system. In this method, two-dimensional electrophoresis and MALDI-TOF MS / MS were used. Statistical analysis was done by t-test and Image master 2D platinum 6.0.

Results: In this study, glyceraldehyde 3-phosphate dehydrogenase expression increased significantly in the biopsy of the higher mean BMI group in comparison with the lower mean BMI=26.04 group (P <0.05). In contrast, the expression of cytokeratin 19 in the higher mean BMI group compared to the other group showed a significant reduction (P <0.05). Furthermore Apo A-1 expressed only in the biopsy of the lower mean BMI group and HSP27 expressed only in the higher mean BMI group.

Conclusion: The findings of this study indicate some differences in protein spectrum between the biopsies of lower and higher mean BMI groups of breast cancer patients. Furthermore the four proteins mentioned in the results probably influence molecular mechanisms linking obesity to breast cancer, but more studies are needed.



Page 1 from 1     

© 2019 All Rights Reserved | J Adv Med Biomed Res

Designed & Developed by : Yektaweb  Co-Publisher: Farname Inc.